Durable Goods (Jun F) -9.4% vs 9.3% Prior, Ex-Trans 0.2% vs 0.2%
On Thursday, Oppenheimer maintained its Perform rating on ResMed (NYSE: RMD) stock following the company’s reported third-quarter fiscal year 2025 earnings. ResMed’s revenue for the quarter increased by 8% year-over-year to $1.292 billion, surpassing both Oppenheimer’s and the consensus estimates of $1.281 billion and $1.288 billion, respectively. The earnings per share (EPS) also exceeded expectations, coming in at $2.48 compared to the anticipated $2.27 and $2.31. With a market capitalization of $31.44 billion and a perfect Piotroski Score of 9, ResMed demonstrates strong financial fundamentals. According to InvestingPro analysis, the company appears undervalued based on its Fair Value estimates.
The company’s gross margin improved both sequentially and year-over-year, up by 70 basis points and 150 basis points, respectively, attributed to manufacturing and distribution efficiencies. The current gross margin stands at a healthy 59.02%, while maintaining a strong current ratio of 3.33, indicating robust operational efficiency and liquidity. Analysts at Oppenheimer highlighted that ResMed is not expected to face any material impact from tariffs, thanks to exemptions under the Nairobi protocol for products related to sleep apnea, respiratory insufficiency, and other chronic respiratory conditions.
Looking ahead, ResMed is set to expand its presence in the United States by opening a new plant in Calabasas in June 2025. The company is also expected to benefit from two significant industry trends that are increasing awareness and adherence to treatment: the use of sleep wearables and GLP-1 medications. However, Oppenheimer analysts caution that GLP-1 medications could present a longer-term challenge to ResMed’s continuous positive airway pressure (CPAP) device business. InvestingPro data reveals the company maintains moderate debt levels and strong cash flows, positioning it well for this expansion. For detailed insights into ResMed’s financial health and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers. While these medications are not seen as an immediate threat, the approval and potential insurance reimbursement for tirzepatide for obstructive sleep apnea (OSA) could change the landscape, with more drugs likely to be approved and potentially become the first-line therapy for obese patients with OSA.
In light of the third-quarter results and the future outlook provided by the company, Oppenheimer is adjusting its estimates for ResMed’s fiscal fourth quarter and full-year 2025. The report from Oppenheimer reflects a cautious but watchful stance on ResMed’s performance amid evolving market conditions and potential industry shifts.
In other recent news, ResMed Inc (NYSE:RMD) reported its Q3 FY2025 earnings, highlighting a mixed performance. The company posted earnings per share (EPS) of $2.37, slightly missing the forecast of $2.39. However, ResMed exceeded revenue expectations, reporting $1.3 billion compared to the anticipated $1.29 billion. The company demonstrated an 8% year-over-year increase in revenue, with device sales growing by 7% globally and mask sales rising by 12%. ResMed also announced plans to expand its manufacturing capabilities with a new facility in Calabasas, California, set to open in June 2025. The company continues to focus on digital health investments and product launches to drive growth. Additionally, ResMed reaffirmed its tariff exemptions, which are expected to mitigate potential impacts from U.S. tariffs on medical devices. The company plans to increase its share buyback program, purchasing shares worth approximately $100 million per quarter starting in Q4 FY2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.